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Abstract At least 22 different mutations associated with early- 
onset familial Alzheimer's disease (AD) in various kindreds have 
been reported to occur in a recently identified gene on 
chromosome 14, presenilin 1 (PS-1) (Sherrington et al. (1995) 
Nature 375, 754-760 [1] and reviewed by Van Broeckhoven 
(1995) Nat. Genet. 11, 230-231 [2]). In order to study the 
localization of PS-1 in the brain, we raised a polyclonal 
antiserum specific to a fragment of the predicted protein 
sequence of PS-1. PS-1 immunostaining was found intracellu- 
lady, in the perikaria of discrete cells, mostly neurons, appearing 
as thick granules, resembling large-size vesicles. These granules 
were located in the periphery of cell bodies and extended into 
dendrites and neurites. PS-1 expression was found to be broadly 
distributed throughout the mouse brain, not only in structures 
involved in AD pathology, but also in structures unaltered by this 
di~ense. 
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1. Introduction 
The study of the inheritable forms of Alzheimer's disease 
(A D) has led to the identification of four genes linked to the 
development of the disease: the 15-amyloid precursor protein 
(I]~_PP) on chromosome 21 [3], apolipoprotein E on chromo- 
some 19 [4], and presenilin 1 and 2 (PS-1 and PS-2) on chro- 
mosomes 14 [1] and 1 [5,6] respectively. The proteins encoded 
b3 the presenilin genes are 467 (PS-1) and 448 (PS-2) amino 
acids long. They display a similar hydrophobicity profile, with 
at least seven highly hydrophobic stretches of approx. 20 re- 
sitiues which constitute putative transmembrane segments. PS- 
I and PS-2 display a high homology in the putative mem- 
brane-spanning domains (61-100% identity). The primary 
structure of the presenilins uggests that these are integral 
m,~mbrane proteins, but their precise molecular function re- 
mains to be determined. The existence of a moderate but 
significant amino acid similarity between the presenilins and 
spe4, a Caenorhabditis elegans gene involved in the transport 
and partitioning of cellular constituents during spermatogen- 
es~s, has led to the proposal that the presenilins might parti- 
cipate in intracellular protein transport [1]. Homology with 
another C. elegans gene sell2 (48% amino acid similarity), 
which facilitates ignalling mediated by lin 12/Notch, suggested 
that the presenilins might be involved in the transduction 
pathway of the l inl2/Notch family [7]. 
The analysis of the expression pattern of the presenilins in 
the brain is an important step in the understanding of both 
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the physiological function of these proteins and their role in 
the pathophysiology of AD. Furthermore, the subcellular lo- 
calisation of the presenilins will provide insights into their 
biological function. We developed a specific polyclonal anti- 
serum raised against a fragment of the predicted protein se- 
quence of PS-1. We describe here the distribution and subcel- 
lular localisation of PS-1 protein in the mouse brain. 
2. Materials and methods 
2.1. Antiserum production 
Peptide (340-356: EAQRDSHLGPHRSTPE) from the sequence of 
PS-1 protein (PS-1(340_356)) was synthesized on a model 431 peptide 
synthesizer (Applied Biosystems) and then purified by reverse-phase 
chromatography. Before immunization, the peptide was coupled to 
RSA. Male New Zealand rabbits (2-3 kg) were immunized by sub- 
cutaneous injections of 1 mg of the immunogen emulsified in Freund's 
complete adjuvant; injections were repeated 28, 56, 84, and 112 days 
after the initial one. The animals were bled after each boost. Solid- 
phase ELISA was used to titrate the antibodies of all the bleedings (1- 
4). Plates were coated with the peptide P5-1(340_356) used at 10 -3 mg 
well -1. After incubation with the anti-PS-l(340_3,~6) antiserum used at 
dilutions ranging from 1:100 to 1:100000 and washing, secondary 
antiserum (goat anti-rabbit IgG) coupled to alkaline phosphatase 
(1:1000 dilution) was added and, after the addition of 4-nitrophenyl 
phosphate in diethanolamine, the optical density was measured at 405 
nm. For immunoprecipitation and immunohistochemistry experi- 
ments, we used the antiserum of rabbit 1331. 
2.2. Immunoprecipitation f PS-1 protein from & vitro translated 
material 
The coding sequence of PS-1 was amplified from human cell line 
cDNA (KCN-SMS) using standard PCR techniques. After subcloning 
in pCRII (Invitrogen), the amplified cDNA was sequenced and the 5' 
end of the coding sequence modified by introducing a Kozak transla- 
tion initiation sequence. The coding sequence was further subcloned 
in the pBTG vector in between the 5' and 3' untranslated regions of 
the B-globin gene. For in vitro transcription/translation, the DNA 
template was transcribed using T3 RNA polymerase (Promega) as 
described in the suppliers manual. Translation of the mRNA tran- 
script in a cell-free rabbit reticulocyte lysate (Promega) was performed 
according to supplier's instructions. The reaction was carried out for 
60 min at 30°C in the presence of 40 ~tCi of [35S]methionine and 0.5- 
1.0 ~tg transcript. For immunoprecipitation, n vitro translatated PS-1 
was diluted with 300 Ixl of medium buffer (100 mM Tris pH 8.0, 10 
mM EDTA, 0.5% NP-40, 0.5% Triton X-100) and incubated for 2 h 
at room temperature with 2 mg of protein A-Sepharose together with 
5 lal of undiluted rabbit polyclonal anti-PS-1 antiserum. Unbound 
proteins were removed from Sepharose beads by washing three times 
with 10 mM Tris (pH 7.5), 150 mM NaC1, 0.2% NP-40, 2 mM EDTA 
and subsequently twice with 10 mM Tris (pH 7.5), 500 mM NaCI, 
0.2% NP-40, 2 mM EDTA. The precipitate was incubated at room 
temperature for 20 min with Laemmli buffer and fractionated by 8- 
16% gradient SDS-PAGE (Novex). The gels were analyzed by fluor- 
ography (Amplify, Amersham). 
2.3. Immunohistochemistry 
Male Balb C mice (20-25 g) were anaesthetized with sodium pen- 
tobarbital (50 mg/kg ip) and ketamine (40 mg/kg ip). They were per- 
fused through the ascending aorta, first with saline and then with 
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fixative solution containing 4% paraformaldehyde in O. 1 M phosphate 
buffer (pH 7.5). Brains were removed, immersed in the same fixative 
solution for 3 h, then stored for 18 h in 0.1 M phosphate buffer 
containing 20% saccharose, and finally frozen at -30°C. Transverse 
sections of 25 ~tm thickness were cut with a cryomicrotome (Leica) 
and placed in glass vials for immunohistochemistry. Sections were 
preincubated with 0.03% hydrogen peroxide for 30 min, washed and 
then incubated with normal goat serum (10% in PBS) at 19°C for 30 
min. They were further incubated at 4°C for 24 h with the PS- 
1(340_356) antiserum (1331)diluted to 1:100, 1:500, 1:2500, 1:5000 
or 1:10000 in PBS containing 2% normal goat serum and 0.3% Triton 
X-100. After washing with PBS, sections were incubated for 1 h with 
goat anti-rabbit IgG coupled to biotin diluted to 1:400, washed and 
then incubated for 1 h with the complex avidin-horseradish peroxidase 
(Vector Laboratories). Sections were finally incubated for 5-30 min in 
peroxidase substrate solution containing 0.01% hydrogen peroxide, 
0.05% diaminobenzidine tetrahydrochloride (DAB) in 0.1 M Tris buf- 
fer, pH 7.2. They were mounted on slides and dehydrated. 
Control experiments were performed (1) by omitting the primary 
antiserum, (2) by using the preimmune serum, (3) by immunoabsor- 
pion of the primary antiserum with the synthetic peptide PS-1(340_356) 
(preincubation for 18 h of the primary antiserum diluted to 1:2500 in 
presence of 1-1000 p.g of the peptide PS-1(340_3~6) ) before performing 
immunohistochemistry as described above. 
3. Results 
3.1. Immunoprecipitation f  PS-1 in vitro 
The polyclonal antiserum 1331 was raised against a syn- 
thetic peptide corresponding to the amino acid stretch 340- 
356 of the predicted protein sequence of human PS-1. To test 
whether this antiserum had a specific affinity for the full 
length PS-1 protein, we immunoprecipitated in vitro trans- 
lated human PS-1 protein (Fig. 1). PS-1 protein was detected 
after precipitation with the antiserum 1331, but not with the 
preimmune serum of the same rabbit. The Antiserum 1331 did 
not precipitate in vitro translated human PS-2 (not shown). 
The predicted molecular weight of PS-1 is 53 kDa. In addi- 
tion to the expected band at around 50 kDa, we found an 
additional band at 85 kDa and a diffuse high molecular 
weight band. The addition of urea into the loading reduced 
the intensity of the diffuse 85 kDa band and that of diffuse 
high molecular weight and increased the intensity of the 50 
kDa band (data not shown). Therefore, it is likely that the 
additional band at 85 kDa and the diffuse high molecular 
weight band resemble aggregated forms of PS-1. 
3.2. Distribution of  PS-1 protein in the mouse brain (Fig. 2) 
Widespread expression of PS-1 protein was observed in the 
mouse brain. Cells in which PS-1 immunostaining was extre- 
mely dense were found in high numbers in the piriform cortex, 
entorhinal cortex, layers V and II of all cortical areas, hippo- 
campus, dentate gyrus, amygdaloid nuclei, olfactory bulb, tha- 
lamus (paraventricular nd mediodorsal nuclei), septum, hy- 
pothalamus (preoptic, supraoptic and paraventricular nuclei), 
basis pontis, and in moderate number in the pallidum, thala- 
mus (ventromedial nd lateral nuclei) substantia nigra ars re- 
ticulata, reticulotegrnental nucleus pontis, lateral vestibular 
nucleus, cerebellum (lateral and medial nuclei). Neurons with 
much lower density of PS-1 immunostaining were found in 
moderate numbers in the striatum, all layers of colliculis, med- 
ial geniculate nucleus and cerebellum (granule cells of dentate 
fascia), and in much lower numbers in all the other examined 
structures, including for example the layer VI of the cortex 
and substantia nigra pars compacta. No immunostaining 
was found in the white matter (internal and external capsules). 
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Fig. 1. Immunoprecipitation of in vitro translated PS-1. Human PS- 
I mRNA was transcribed from the corresponding plasmid and 
translated in rabbit reticulocyte lysate in the presence of 
[35S]methionine. IVT PS-1 was immunoprecipitated an  analysed by 
SDS-PAGE as described in section 2. Lane 1, IVT PS-1 immuno- 
precipitated with polyclonal antiserum 1331; lane 2, IVT PS-1 im- 
munoprecipitated with the corresponding preimmune serum; KD, 
kilo Dalton. 
There was no cellular immunostaining when the primary 
antiserum was omitted or when the preimmune serum was 
used. Likewise, there was no cellular immunostaining when 
the primary antiserum was first incubated with the synthetic 
peptide at the concentration of 1 mg/ml (Fig. 2). 
3.3. Subcellular localization of PS-1 protein in mouse brain 
(Fig. 2) 
PS 1 immunostaining was found intracellularly, in the peri- 
karia of discrete cells, mostly neurons. It appeared as thick 
granules resembling vesicles, mainly at the periphery of cell 
bodies and in dendrites and neurites. In some, but not all 
neurons, the immunostaining was found around the nucleus. 
When the antiserum was preincubated with increasing 
amounts of PS-1(340__3~6) synthetic peptide, PS-1 immuno- 
staining decreased in all subcellular compartments in a dose- 
specific manner. 
...+ 
Fig. 2. Immunohistochemical mages showing the distribution and 
subcellular localization of PS-1 protein in the mouse brain. PS-1 im- 
munostaining is found in neurons located in various structures. 
(A,C) Transverse sections howing neurons with high density of PS- 
1 immunostaining in the cortex (Ctx), the hippocampus (Hip) the 
globus pallidus (GP). Neurons with lower density are seen in the 
striatum (St). No immunostained cells are found in the white mat- 
ter, internal and external capsule (ic, ec) (× 50). (B) Section adjacent 
to A incubated with the antiserum following absorption with the 
synthetic peptide PS-I(a40-asr) (×50). (D) PS-1 immunostaining is 
found intracellular in neurons of the hippocampus (× 200); (E) sec- 
tion adjacent o D showing no intracellular immunostaining after 
immunoabsorption. (F,G) PS-1 immunostaining appears at high 
magnification (× 1200) as thick granules resembling large-size vesi- 
cles in the cell bodies (arrow in F) and in neuronal processes (ar- 
rows in G). For absorption, 1 mg of synthetic peptide PS-lo40_a~6) 
was incubated with 2 ktl of antiserum in 5 ml of PBS for 18 h 
(4°C). This solution was then used (without centrifugation) to per- 
form immunohistochemistry on brain sections. 
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4. Discussion 
In order to elucidate the specific function of PS-1 and its 
participation in AD physiopathology, we raised a polyclonal 
antiserum (1331) that recognized PS-1 protein both by immu- 
noprecipitation and by immunohistochemical analysis on 
brain sections. This antiserum was raised against a region 
which is conserved between mouse and human PS-1 protein 
sequence. The epitope is not shared by PS-2 and, as expected, 
the antiserum recognized PS-1 and not PS-2. 
Previously a widespread pattern of PS-1 expression had 
been suggested on the basis of Northern-Blot analysis of 
PS-1 mRNA transcript expression [1]. Here we show by im- 
munohistochemical analysis a broad neuronal distribution of 
the PS-1 protein in the brain. The pattern of distribution of 
PS-1 in mice described here is similar to that previously de- 
scribed for I~APP in rats [8], but the exact colocalization of 
these 2 proteins will require double labelling studies. PS-1 is 
found not only in regions of the brain that display senile 
plaques and/or neurofibrillary tangles in AD, such as the cor- 
tex and the hippocampus, but also in regions little or not at 
all affected by the disease, such as the striatum and the cere- 
bellum. However, preamyloid eposits are much more widely 
distributed than senile plaques throughout the central nervous 
system [9]. All these data together may indicate either that 
expression of I3APP and PS-1 proteins are not the only factors 
responsible for neurodegeneration in affected structures, or 
that there are endogenous mechanisms protecting neurons in 
unaffected stuctures in AD brains. 
Furthermore, the wide neuronal expression of PS-1 protein 
suggests that it may play a physiological role in neurons. It 
has been suggested that PS-1 interacts with mammalian Notch 
by studies on PS-1 homologs in nematode [7], but this cannot 
be the sole function of PS-1 protein. The mammalian forms of 
Notch are expressed in limited neuronal structures [10], and 
are not found in most of the neurons where PS-1 protein is 
expressed. 
PS-1 immunostaining is localized intracellularly as recently 
described in transfected cells by Kovacs et al. [11]. PS-1 im- 
munostaining appears as thick granules resembling vesicles 
located mainly at the periphery of cell bodies, and occasion- 
ally around the nucleus. This granular staining extended into 
neuronal processes, an observation that further suggests its 
vesicular sublocalization. The intracellular localization of 
PS-1 protein in neurons and its presence in neurites indicate 
that it may participate in neuritic transport. 
The determination of the distribution and subcellular loca- 
lization of PS-1 protein in mouse brain should be of value in 
clarifying the mechanisms by which mutations in the PS-1 
gene lead to AD and therefore the selective neuronal vulner- 
ability observed in AD patients. 
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